The run-in phase of the prospective WSG-ADAPT HR+/HER2– trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer

BACKGROUND: Endocrine sensitivity, as determined by response of the proliferation marker Ki-67 to short-term preoperative endocrine therapy (ET), is currently not included in adjuvant treatment decisions in hormone receptor (HR)+/human epidermal growth factor receptor 2 (HER2)− breast cancer (BC). M...

Descripción completa

Detalles Bibliográficos
Autores principales: Nitz, Ulrike, Gluz, Oleg, Kreipe, Hans H., Christgen, Matthias, Kuemmel, Sherko, Baehner, Frederick L., Shak, Steven, Aktas, Bahriye, Braun, Michael, Lüdtke-Heckenkamp, Kerstin, Forstbauer, Helmut, Grischke, Eva-Maria, Nuding, Benno, Darsow, Maren, Schumacher, Claudia, Krauss, Katja, Malter, Wolfram, Thill, Marc, Warm, Mathias, Wuerstlein, Rachel, Kates, Ronald E., Harbeck, Nadia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7692353/
https://www.ncbi.nlm.nih.gov/pubmed/33281950
http://dx.doi.org/10.1177/1758835920973130

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7692353/
https://www.ncbi.nlm.nih.gov/pubmed/33281950
http://dx.doi.org/10.1177/1758835920973130

Ejemplares similares